A Randomized, Placebo-Controlled Study to Assess Safety and Efficacy of Vardenafil 10mg and Tamsulosin 0.4mg vs. Tamsulosin 0.4mg Alone in the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia

Journal of Sexual Medicine

Volumn 9, Issue 6, 2012, Pages 1624-1633

  Gacci, Mauro ^a   Vittori, Gianni ^a   Tosi, Nicola ^a   Siena, Giampaolo ^a   Rossetti, Mario Alberto ^a   Lapini, Alberto ^a   Vignozzi, Linda ^a   Serni, Sergio ^a   Maggi, Mario ^a   Carini, Marco ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Benign prostatic hyperplasia; Erectile dysfunction; Lower urinary tract symptoms; PDE5; Tamsulosin; Vardenafil

Indexed keywords

PHOSPHODIESTERASE; PLACEBO; TAMSULOSIN; VARDENAFIL;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; FEMALE; FLANK PAIN; FLUSHING; FOLLOW UP; HUMAN; INTERNATIONAL INDEX OF ERECTILE FUNCTION; INTERNATIONAL PROSTATE SYMPTOM SCORE; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVER ACTIVE BLADDER QUESTIONNAIRE; PENIS ERECTION; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RESIDUAL URINE; SIDE EFFECT; STOMACH PAIN; SYNCOPE; THERAPY EFFECT; URINE VOLUME; UROFLOWMETRY;

EID: 84861808111     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2012.02718.x     Document Type: Article

References (34)

1. Gacci M, Bartoletti R, Figlioli S, Sarti E, Eisner B, Boddi V, Rizzo M. Urinary symptoms, quality of life and sexual function in patients with benign prostatic hypertrophy before and after prostatectomy: A prospective study. BJU Int 2003;91:196-200.
2. Gacci M, Eardley I, Giuliano F, Hatzichristou D, Kaplan S, Maggi M, McVary K, Mirone V, Porst H, Roehrborn C. Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol 2011;60:809-25.
3. McVary KT. Erectile dysfunction and lower urinary tract symptoms secondary to BPH. Eur Urol 2005;47:838-45.
4. Madersbacher S, Marszalek M, Lackner J, Berger P, Schatzl G. The long-term outcome of medical therapy for BPH. Eur Urol 2007;51:1522-33.
5. Michel MC, Bressel HU, Mehlburger L, Goepel M. Tamsulosin: Real life clinical experience in 19, 365 patients. Eur Urol 1998;34(2 suppl):37-45.
6. Michel MC, Bressel HU, Goepel M, Rübben H. A 6-month large-scale study into the safety of tamsulosin. Br J Clin Pharmacol 2001;51:609-14.
7. Höfner K, Claes H, De Reijke TM, Folkestad B, Speakman MJ. Tamsulosin 0.4mg once daily: Effect on sexual function in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 1999;36:335-41.
8. Filippi S, Morelli A, Sandner P, Fibbi B, Mancina R, Marini M, Gacci M, Vignozzi L, Vannelli GB, Carini M, Forti G, Maggi M. Characterization and functional role of androgen-dependent PDE5 activity in the bladder. Endocrinology 2007;148:1019-29.
9. Fibbi B, Morelli A, Vignozzi L, Filippi S, Chavalmane A, De Vita G, Marini M, Gacci M, Vannelli GB, Sandner P, Maggi M. Characterization of phosphodiesterase type 5 expression and functional activity in the human male lower urinary tract. J Sex Med 2010;7(1 Pt 1):59-69.
10. Morelli A, Filippi S, Sandner P, Fibbi B, Chavalmane AK, Silvestrini E, Sarchielli E, Vignozzi L, Gacci M, Carini M, Vannelli GB, Maggi M. Vardenafil modulates bladder contractility through cGMP-mediated inhibition of RhoA/Rho kinase signaling pathway in spontaneously hypertensive rats. J Sex Med 2009;6:1594-608.
11. Gacci M, Del Popolo G, Macchiarella A, Celso M, Vittori G, Lapini A, Serni S, Sandner P, Maggi M, Carini M. Vardenafil improves urodynamic parameters in men with spinal cord injury: Results from a single dose, pilot study. J Urol 2007;178:2040-3, discussion 2044.
12. Gacci M, Ierardi A, Rose AD, Tazzioli S, Scapaticci E, Filippi S, Maggi M, Nicita G, Carini M, Montorsi F. Vardenafil can improve continence recovery after bilateral nerve sparing prostatectomy: Results of a randomized, double blind, placebo-controlled pilot study. J Sex Med 2010;7(1 Pt 1):234-43.
13. Speakman MJ. PDE5 inhibitors in the treatment of LUTS. Curr Pharm Des 2009;15:3502-5.
14. Wang C. Phosphodiesterase-5 inhibitors and benign prostatic hyperplasia. Curr Opin Urol 2010;20:49-54.
15. Auerbach SM, Gittelman M, Mazzu A, Cihon F, Sundaresan P, White WB. Simultaneous administration of vardenafil and tamsulosin does not induce clinically significant hypotension in patients with benign prostatic hyperplasia. Urology 2004;64:998-1003, discussion 1003-4.
16. Barry MJ, Fowler FJ Jr, O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, Cockett AT. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 1992;148:1549-57, discussion 1564.
17. Coyne K, Revicki D, Hunt T, Corey R, Stewart W, Bentkover J, Kurth H, Abrams P. Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: The OAB-q. Qual Life Res 2002;11:563-74.
18. Stief CG, Porst H, Neuser D, Beneke M, Ulbrich E. A randomized, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol 2008;53:1236-44.
19. Alan W, Shindel MD. 2009 update on phosphodiesterase type 5 inhibitor therapy part 1: Recent studies on routine dosing for penile rehabilitation, lower urinary tract symptoms, and other indications. J Sex Med 2009;6:1794-808.
20. Oger S, Behr-Roussel D, Gorny D, Lecoz O, Lebret T, Denoux Y, Faix A, Leriche A, Wayman C, Alexandre L, Giuliano F. Combination of doxazosin and sildenafil exerts an additive relaxing effect compared to each compound alone on human cavernosal and prostatic tissue. J Sex Med 2009;6:836-47. 2008.
21. Liguori G, Trombetta C, De Giorgi G, Pomara G, Maio G, Vecchio D, Ocello G, Ollandini G, Bucci S, Belgrano E. Efficacy and safety of combined oral therapy with tadalafil and alfuzosin: An integrated approach to the preliminary report. J Sex Med 2009;6:544-52.
22. McVary KT, Monnig W, Camps JL Jr, Young JM, Tseng L-J, Van Den Eeden G. Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: A randomized double-blind trial. J Urol 2007;177:1071-7.
23. Bechara A, Romano S, Casabé A, Haime S, Dedola P, Hernández C, Rey H. Comparative efficacy assessment of tamsulosin vs. tamsulosin plus tadalafil in the treatment of LUTS/BPH. Pilot study. J Sex Med 2008;5:2170-8.
24. McVary K, Roehborn C, Kaminetsky J, Auerbach S, Wachs B, Young J, Esler A, Sides G, Denes B. Tadalafil relieves lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). J Urol 2007;177:1401-7.
25. Tuncel A, Nalcacioglu V, Ener K, Aslan Y, Aydin O, Atan A. Sildenafil citrate and tamsulosin combination is not superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. World J Urol 2010;28:17-22.
26. Kaplan S, Gonzalez R, Te A. Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. Eur Urol 2007;51:1717-23.
27. Morelli A, Filippi S, Comeglio P, Sarchielli E, Chavalmane AK, Vignozzi L, Fibbi B, Silvestrini E, Sandner P, Gacci M, Carini M, Vannelli GB, Maggi M. Acute vardenafil administration improves bladder oxygenation in spontaneously hypertensive rats. J Sex Med 2010;7(1 Pt 1):107-20.
28. Morelli A, Sarchielli E, Comeglio P, Filippi S, Mancina R, Gacci M, Vignozzi L, Carini M, Vannelli GB, Maggi M. Phosphodiesterase type 5 expression in human and rat lower urinary tract tissues and the effect of tadalafil on prostate gland oxygenation in spontaneously hypertensive rats. J Sex Med 2011;8:2746-60.
29. Güler C, Tüzel E, Doǧantekin E, Kiziltepe G. Does sildenafil affect uroflowmetry values in men with lower urinary tract symptoms suggestive of benign prostatic enlargement? Urol Int 2008;80:181-5. Epub 2008 Mar 19.
30. Chung BH, Lee JY, Lee SH, Yoo SJ, Lee SW, Oh CY. Safety and efficacy of the simultaneous administration of udenafil and an alpha-blocker in men with erectile dysfunction concomitant with BPH/LUTS. Int J Impot Res 2009;21:122-8.
31. Broderick GA, Brock GB, Roehrborn CG, Watts SD, Elion-Mboussa A, Viktrup L. Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia in men with or without erectile dysfunction. Urology 2010;75:1452-8.
32. Montorsi F, Brock G, Lee J, Shapiro J, van Poppel H, Graefen M, Stief C. Effect of nightly versus on-demand vardenafil on recovery of erectile function in men following bilateral nerve-sparing radicalprostatectomy. Eur Urol 2008;54:924-31.
33. Porst H, Sharlip ID, Hatzichristou D, Rubio-Aurioles E, Gittelman M, Stancil BN, Smith PM, Wilkins HJ, Pommerville P; Vardenafil Study Group. Extended duration of efficacy of vardenafil when taken 8 hours before intercourse: A randomized, double-blind, placebo-controlled study. Eur Urol 2006;50:1086-95.
34. Kloner R, Jackson G, Emmick J, Mitchell M, Bedding A, Warner L, Pereira A. Interaction between the phosphodiesterase 5 inhibitor. Tadalafil and 2 alfa-blockers, doxazosin and tamsulosin in healthy normotensive men. J Urol 2004;172:1935-40.